HIV/AIDS

Clinical Research

NIAID supports six clinical trial networks that conduct domestic and international human studies focused on the institute’s highest HIV/AIDS research priorities including:

• New HIV prevention methods
• Vaccine research and development
• Microbicides to prevent HIV acquisition and transmission
• Strategies to prevent mother-to-child HIV transmission
• New drug development and optimizing clinical management of HIV/AIDS, including co-morbidities.

The clinical trial networks include:

• The AIDS Clinical Trials Group (ACTG)
• The HIV Prevention Trials Network (HPTN)
• The HIV Vaccine Trials Network (HVTN)
• The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
• The International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
• The Microbicide Trials Network (MTN)

Each network consists of a clinical trial unit led by a principal investigator and features an administrative component, community advisory board and one or more clinical research sites, such as medical schools, academic health centers, hospitals or outpatient centers, where the clinical trials are performed. For a complete listing of all of the clinical trial units and sites, see: HIV/AIDS Network Clinical Trials Units (CTU) and Clinical Research Sites (CRS).

Vaccine Research Center Studies

In addition to the six HIV/AIDS clinical trial networks, NIAID also conducts early stage HIV vaccine research through its Dale and Betty Bumpers Vaccine Research Center (VRC) on the NIH campus in Bethesda, Md. The VRC Clinical Trials Core Laboratory performs Phase I human research of HIV vaccines developed at the VRC.

For information about current federally funded and privately sponsored HIV/AIDS clinical trials, see AIDSinfo or ClinicalTrials.gov.

back to top